Physician profile
Stephen Meyerhuber
NPI 1235227299
$2,714.66
in general payments reported to CMS, 2019-2025
22 companies · $858 in 2025
The $858 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.25 · 2020: $18.88 · 2021: $247 · 2022: $443 · 2023: $502 · 2024: $632 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,030.96 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $228.47 | 2022-2025 | Tremfya, Simponi, Stelara |
| Regeneron Healthcare Solutions, INC. | $182.94 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $166.21 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $144.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Fresenius Kabi USA, LLC | $121.55 | 2023-2025 | Adalimumab-Aacf, Idacio |
| Intercept Pharmaceuticals, INC. | $120.26 | 2022-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.94 | 2019-2024 | Trulance, Xifaxan |
| Ardelyx, INC. | $87.38 | 2023 | Ibsrela |
| Qol Medical, LLC | $87.09 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $84.88 | 2024-2025 | |
| Abbvie INC. | $84.20 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $64.68 | 2022-2023 | Dificid, Zinplava |
| Redhill Biopharma INC. | $42.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $31.87 | 2022-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $28.19 | 2024 | Monoferric |
| Amgen INC. | $22.86 | 2022 | |
| Braintree Laboratories, INC. | $20.92 | 2023 | Sutab |
| Alnylam Pharmaceuticals INC. | $16.69 | 2025 | Givlaari |
| Aimmune Therapeutics, INC. | $15.21 | 2024 | |
| Eagle Pharmaceuticals, INC. | $14.65 | 2024 | |
| Organon LLC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Meyerhuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.